Actively Recruiting
A Study to Learn About the Medicine Called PF-08653944 in People With and Without Reduced Liver Function
Led by Pfizer · Updated on 2026-04-23
26
Participants Needed
3
Research Sites
64 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is being done to learn more about an investigational medicine called PF-08653944. The goal is to understand how the body handles the medicine and to check its safety after a single dose. The study includes adults with normal liver function and adults who have mild, moderate, or severe liver problems. By comparing these groups, researchers want to understand whether liver function changes how the medicine behaves in the body. People who join the study will receive one injection of the study medicine. They will stay at the study clinic for a short time and return for follow-up visits so doctors can do blood tests, physical exams, and safety checks. This study is not expected to provide direct medical benefit to participants. The information collected will help researchers develop future treatments and understand how this medicine may be used safely in people with liver disease.
CONDITIONS
Official Title
A Study to Learn About the Medicine Called PF-08653944 in People With and Without Reduced Liver Function
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults 18 to 75 years of age, male or female
- BMI 6521 kg/m�b2 and body weight over 50 kg at screening
- No known or suspected hepatic impairment and normal liver function tests for group without hepatic impairment
- Stable hepatic impairment classified as Child-Pugh Class A (mild), B (moderate), or C (severe) for hepatic impairment groups
- No clinically significant worsening of hepatic status within 28 days prior to screening
- Women of childbearing potential must not be pregnant or breastfeeding and must agree to use highly effective contraception
You will not qualify if you...
- Clinically significant medical or psychiatric conditions, including recent or active suicidal ideation or behavior
- Use of GLP-1 receptor agonists within 90 days prior to dosing
- Participation in another investigational study or receipt of an investigational product within 30 days prior to dosing
- For hepatic-impairment groups only: hepatic carcinoma, hepatorenal syndrome, or limited life expectancy
- Clinically active Grade 3 or 4 hepatic encephalopathy
- Severe uncontrolled ascites, recent gastrointestinal bleeding, or history of solid organ transplant
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Floridian Clinical Research
Miami Lakes, Florida, United States, 33016
Actively Recruiting
2
Orlando Clinical Research Center
Orlando, Florida, United States, 32809
Actively Recruiting
3
Genesis Clinical Research
Tampa, Florida, United States, 33603
Actively Recruiting
Research Team
P
Pfizer CT.gov Call Center
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here